Ashraf appointed as division director of Pediatric Endocrinology

UAB and Children’s of Alabama have named the new director of Pediatric Endocrinology.
Written by: Hannah Bae
Media contact: Savannah Koplon


Ashraf Ambika 1134232226Ambika Ashraf, M.D.Ambika Ashraf, M.D., has been named director of the Division of Pediatric Endocrinology in the University of Alabama at Birmingham Department of Pediatrics and Children’s of Alabama.

Ashraf joined the faculty at UAB and Children’s in 2006 after completing her fellowship in pediatric endocrinology in the University of Alabama at Birmingham School of Medicine. Her clinical interests include lipid disorders, bone metabolism and endocrine disorders of children and adolescents. Ashraf has been recognized as an international authority on lipid disorders.

“We are excited to have Dr. Ashraf lead in her new role, and she is poised to take it on,” said Mitch Cohen, M.D., chair of the Department of Pediatrics at the UAB School of Medicine and physician-in-chief of Children’s. “I believe that, under Dr. Ashraf’s leadership, the division will provide even more outstanding care, train the next generation of pediatric endocrinologists, and achieve a new level of investigation and scholarly contributions to our academic mission.”

After receiving her MBBS and M.D. from the University of Calicut in Kerala, India, Ashraf completed her pediatric residency training from Bronx-Lebanon Hospital, New York, and the University of Alabama at Birmingham. Ashraf currently serves as director of the Pediatric Lipid Clinic and associate director of the Metabolic Bone Clinic at Children’s, as well as scientist in the UAB Comprehensive Diabetes Center. Her research interests include diabetes mellitus, lipid metabolism, and disorders of calcium and vitamin D.

“I am honored to be the next director of such an important and distinguished division and to grow in this role at UAB and Children’s,” Ashraf said. “I look forward to continuing to work with my colleagues at both institutions to strengthen our clinical initiatives, continue groundbreaking research and provide the utmost care for our patients moving forward.”